$SMMT Hits 52-Week Lows After the FDA Says No: The Survival Math That Sank Ivonescimab, the $630 Million Cash Clock, and the Zones From $7 to $26
The FDA rejected ivonescimab, the drug that beat Keytruda in China, because PFS without significant survival data no longer clears the bar. Summit still trades at $9.7B with $630M cash and a binary HARMONi-3 readout due this quarter. The runway math and scenario zones from $7 to $26.
On Sunday, November 15, Summit Therapeutics announced that the FDA had issued a Complete Response Letter for ivonescimab, its bispecific antibody targeting PD-1 and VEGF, in patients with EGFR-mutated non-small cell lung cancer who have progressed after TKI therapy. The PDUFA date was Saturday, November 14. The agency's answer was no: the application cannot be approved in its present form, because a progression-free survival benefit without a statistically significant overall survival improvement does not, in the FDA's judgment, establish substantial evidence of effectiveness.
The market saw it coming. Summit closed at $17.83 on Tuesday, November 10, then fell three straight sessions into the decision, finishing Friday at $14.15, a 21 percent slide on rising volume. Monday premarket, the stock is trading around $12.15, down another 14 percent and sitting almost exactly on its 52-week low of $12.07 from mid-August. A name that touched $29.23 in April has lost nearly 60 percent from that high, and the final leg came on the single document the entire 2026 thesis was built around.
That is why the ticker is trending this morning. The question the stream is wrestling with is the right one: after a rejection, is Summit still a $9.7 billion platform story with four more shots on goal, or is it a pre-revenue biotech with a nine-figure quarterly loss and a cash clock that just started ticking much louder?
What the FDA actually said
The precise wording matters here, because the CRL is not a verdict on whether ivonescimab works. It is a verdict on which evidence counts.
The application rested on HARMONi, a global Phase III trial of ivonescimab plus chemotherapy in EGFR-mutant NSCLC patients who had failed a tyrosine kinase inhibitor. The trial met its progression-free survival endpoint with a statistically significant improvement. Overall survival, the other primary endpoint, showed a positive trend at the primary analysis but did not reach statistical significance. In longer-term follow-up, the company reported a post-hoc overall survival hazard ratio of 0.76, consistent across the full population, Asian patients, and Western patients.
The FDA's position, as described in Summit's own announcement, is that in this treatment setting PFS alone does not carry the application, and a post-hoc survival analysis cannot substitute for a prespecified statistically significant one. Safety was not the problem: treatment-related discontinuations ran 7.3 percent versus 5.0 percent in the control arm, and treatment-related deaths were actually lower in the ivonescimab arm, 1.8 percent versus 2.3 percent.
In other words, the agency drew a hard statistical line, and the drug landed on the wrong side of it by the rules that were prespecified. "We are disappointed for patients and families awaiting treatment options," said Robert Duggan, Summit's Chairman and Co-CEO, in the release.
Briefings like this are free to read with a free AlphaBriefing membership. Join free.
Why this stings more than a normal CRL
Ivonescimab was not a lottery-ticket asset. This is the molecule that famously beat Keytruda head-to-head on progression-free survival in HARMONi-2, a China-only trial run by Summit's partner Akeso and reported in late 2024, the result that turned Summit from a shell with cash into one of the most-watched stories in biotech. Summit licensed Western and Japanese rights from Akeso in a late-2022 deal worth $500 million upfront and up to roughly $5 billion overall. More than 100,000 patients have been treated commercially in China, where the drug is approved. Approval here would have been Summit's first marketed product anywhere and ivonescimab's first Western authorization.
Instead, the first US regulatory test of the PD-1xVEGF class ended in a rejection, and the readthrough question now hangs over every bispecific chasing the same mechanism.
What happens next is not a mystery in direction, only in timing and magnitude. The trades from here are mechanical: how long $630 million lasts against a loss rate above $200 million a quarter, what exactly has to happen in HARMONi-3 for the story to be repaired, which dates those answers arrive on, and what price zones correspond to each branch of the tree.
A free membership gets you access to every free article at AlphaBriefing.com: Join AlphaBriefing.
The rest of this briefing is for paid members: the cash runway math against the Q3 numbers, the HARMONi-3 date math and what the FDA's own letter tells us it must show, the dilution mechanics at 52-week lows, and the scenario-by-scenario price zones from $7 to $26.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish, the analysis private intel clients pay four figures for, at a fraction of that.